Scope of report
- The report provides a snapshot of the global therapeutic landscape of Huntington’s disease.
- The report assesses Huntington’s disease pipeline based on highest phase of development, type of sponsor, mechanism of action (MoA), route of administration (RoA), and molecule type.
- The report reviews Huntington’s disease pipeline by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The report covers pipeline products based on various stages of development for Huntington’s disease ranging from discovery to pre-registration and undisclosed stages.
Eli Lilly, Scios, Otsuka Pharmaceutical, Regeneron Pharmaceuticals, Ceregene, Genzyme Corporation, Cogent Neuroscience [CEASED], Ipsen, Vertex Pharmaceuticals, NeuroSearch Sweden AB, ReNeuron, Tapestry Pharmaceuticals, Prana Biotechnology, TopoTarget, NeuroNova AB, Almirall-Prodesfarma; Neurocrine Biosciences, Sirtris Pharmaceuticals, Medivation, irna Therapeutics, Targeted Genetics, SYGNIS Bioscience GmbH
Remacemide, LY 274614, NPC 12626, OPC 14117, Dapiclermin, CERE 120, ZVAD fmk, Porcine neural cell product-HD, Tetrathiomolybdate, AM 404, BN 82451, VX 563, Pridopidine, HD 1 – Tapestry Pharmaceuticals, PBT 2, Latrepirdine
Format: Microsoft Excel
- Single Use: $300
- Site License: $500
- Global License: $800